Becton Dickinson – Buy For Its Long-Term Growth Opportunities
Summary Becton Dickinson released its Q4 and FY2018 results and FY2019 Guidance on November 6th. Integration of Carefusion and C.R. Bard is proceeding as planned and management expects strong underlying growth of approximately 16% - 17% on a currency-neutral basis which is in excess of the C.R. Bard deal model. BDX expects to deliver adjusted [...]